IRIS
BALESTRIERI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.635
NA - Nord America 675
EU - Europa 345
SA - Sud America 208
AF - Africa 23
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.890
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 988
US - Stati Uniti d'America 618
CN - Cina 247
IT - Italia 175
BR - Brasile 152
VN - Vietnam 137
HK - Hong Kong 112
BD - Bangladesh 67
FR - Francia 45
GB - Regno Unito 39
DE - Germania 28
MX - Messico 25
CA - Canada 22
AR - Argentina 19
IN - India 17
EC - Ecuador 12
NL - Olanda 12
ID - Indonesia 11
RU - Federazione Russa 10
CO - Colombia 8
PL - Polonia 7
ZA - Sudafrica 7
JP - Giappone 6
PK - Pakistan 6
UA - Ucraina 6
ES - Italia 5
IQ - Iraq 5
PH - Filippine 5
TR - Turchia 5
IR - Iran 4
PE - Perù 4
PY - Paraguay 4
SA - Arabia Saudita 4
TN - Tunisia 4
VE - Venezuela 4
AU - Australia 3
AZ - Azerbaigian 3
CL - Cile 3
CZ - Repubblica Ceca 3
MY - Malesia 3
SE - Svezia 3
UZ - Uzbekistan 3
AM - Armenia 2
AT - Austria 2
BO - Bolivia 2
BW - Botswana 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
FI - Finlandia 2
JO - Giordania 2
KZ - Kazakistan 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
SI - Slovenia 2
BB - Barbados 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
ME - Montenegro 1
MG - Madagascar 1
MQ - Martinica 1
RO - Romania 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
Totale 2.890
Salva come PNG Salva come JPEG
Città #
San Jose 235
Singapore 186
Ashburn 131
Hong Kong 107
Rome 107
Beijing 80
Hefei 68
Ho Chi Minh City 51
Lauterbourg 38
Boardman 35
Hanoi 35
London 30
Dallas 29
Shanghai 22
Mexico City 15
New York 14
Santa Clara 14
São Paulo 14
Los Angeles 12
Council Bluffs 11
Amsterdam 7
Munich 7
Warsaw 7
Milan 6
Nuremberg 6
Rio de Janeiro 6
San Francisco 6
Seattle 6
Toronto 6
Brooklyn 5
Buffalo 5
Quito 5
Tokyo 5
Boydton 4
Brasília 4
Buenos Aires 4
Catania 4
Chicago 4
Da Nang 4
Orem 4
Pune 4
Bauru 3
Biên Hòa 3
Bắc Giang 3
Cagliari 3
Charlotte 3
Guarulhos 3
Hamburg 3
Johannesburg 3
Lima 3
Markham 3
Naples 3
Paris 3
Phoenix 3
Stockholm 3
Turin 3
Amman 2
Apodaca 2
Asunción 2
Atibaia 2
Baghdad 2
Baku 2
Banī Suwayf 2
Bari 2
Barquisimeto 2
Berlin 2
Bogotá 2
Boston 2
Brno 2
Bắc Ninh 2
Canberra 2
Canela 2
Caracas 2
Caxias do Sul 2
Chennai 2
Cotia 2
Curitiba 2
Dagenham 2
Dhaka 2
Formosa 2
Frankfurt am Main 2
Guiyang 2
Haiphong 2
Hưng Yên 2
Itapevi 2
Jeddah 2
Kuala Lumpur 2
La Paz 2
Las Vegas 2
Limeira 2
Liverpool 2
Ljubljana 2
Magé 2
Maicao 2
Maitengwe 2
Medellín 2
Mississauga 2
Montreal 2
Moscow 2
Mumbai 2
Totale 1.476
Salva come PNG Salva come JPEG
Nome #
Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients 240
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 225
Wall Thickness Ratio—A New Magnetic Resonance Parameter—Is Associated With the Outcome of Biological Therapy in Patients With Ileal and Ileocolonic Crohn’s Disease 136
Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in non-erosive reflux disease patients 129
Mathematical Modeling of Vedolizumab Treatment’s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients 119
Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients 98
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease 93
Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults 87
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 86
Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases 71
Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy 71
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study 69
Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study 68
Impedance-High Resolution Manometry Analysis of Patients With Nonerosive Reflux Disease 67
Psychological distress in inflammatory bowel disease 67
Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease 66
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 65
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 61
The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough 60
Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. 60
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 58
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy 53
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 52
Adalimumab in active ulcerative colitis: A "real-life" observational study 52
Ultrasonography Tight Control and Monitoring in Crohn’s Disease During Different Biological Therapies: A Multicenter Study 51
Intra-bolus pressure and esophagogastric gradient, assessed with high-resolution manometry, are associated with acid exposure and proximal migration of refluxate 50
Therapeutic adherence in inflammatory bowel disease: User guide from a multidisciplinary modified Delphi consensus 48
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 46
Weak peristalsis with large breaks is associated with higher acid exposure and delayed reflux clearance in the supine position in GERD patients 46
Nutritional aspects in inflammatory bowel diseases 45
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS‐CoV‐2 infection: an IG‐IBD study 44
Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responder to proton pump inhibitors 44
Role of Esophageal Motility, Acid Reflux, and of Acid Suppression in Nonobstructive Dysphagia 44
Reflux Patterns and Role of Impedance-pH Variables in Predicting PPI Response in Patients With Suspected GERD-Related Chronic Cough 43
High-resolution Manometry Findings During Solid Swallows Correlate With Delayed Reflux Clearance and Acid Exposure Time in Non-erosive Reflux Disease Patients 43
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 42
Role of Overweight and Obesity in Gastrointestinal Disease 41
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 39
Role of Mixed Reflux and Hypomotility with Delayed Reflux Clearance in Patients with Non-cardiac Chest Pain 37
Understanding the relationship between esophageal motor disorders and reflux disease 35
REFLUX PATTERN AND ROLE OF IMPEDANCE-PH VARIABLES IN PREDICTING PPI RESPONSE IN PATIENTS WITH SUSPECTED GERD-RELATED CHRONIC COUGH 34
Patients With Extra-Esophageal Symptoms, Compared to NERD Patients With Typical Symptoms and Healthy Volunteers, Arc Characterized by a Higher Number of Reflux Episodes and Higher Proportion of Weakly Acidic and Mixed Reflux 30
Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: An observational multicentre study 27
Totale 2.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202232 0 0 4 0 0 0 0 0 0 0 0 28
2022/202310 0 0 0 0 1 0 0 0 1 0 8 0
2023/202494 4 11 3 5 6 37 3 6 0 7 9 3
2024/20251.031 22 8 37 3 11 23 23 3 72 71 301 457
2025/20261.775 159 116 173 272 80 74 345 98 165 133 85 75
Totale 2.942